Zacks Investment Research upgraded shares of SeaSpine Holdings Corporation (NASDAQ:SPNE) from a hold rating to a buy rating in a report released on Wednesday morning. They currently have $12.00 target price on the medical equipment provider’s stock.

According to Zacks, “SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. “

A number of other research analysts also recently issued reports on SPNE. HC Wainwright set a $15.00 price objective on shares of SeaSpine Holdings Corporation and gave the stock a buy rating in a research report on Monday, August 7th. Piper Jaffray Companies reaffirmed a buy rating and issued a $22.00 price objective on shares of SeaSpine Holdings Corporation in a research report on Sunday, August 20th. Finally, BTIG Research reaffirmed a buy rating on shares of SeaSpine Holdings Corporation in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. SeaSpine Holdings Corporation currently has an average rating of Buy and an average price target of $16.33.

Shares of SeaSpine Holdings Corporation (NASDAQ:SPNE) traded down $0.01 during trading on Wednesday, hitting $10.41. 41,700 shares of the stock were exchanged, compared to its average volume of 59,577. SeaSpine Holdings Corporation has a 52-week low of $6.31 and a 52-week high of $13.46.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/seaspine-holdings-corporation-spne-raised-to-buy-at-zacks-investment-research/1696297.html.

A number of hedge funds have recently added to or reduced their stakes in SPNE. Synovus Financial Corp acquired a new stake in SeaSpine Holdings Corporation in the 2nd quarter worth approximately $116,000. Virtu KCG Holdings LLC acquired a new stake in SeaSpine Holdings Corporation in the 2nd quarter worth approximately $133,000. Goldman Sachs Group Inc. acquired a new stake in SeaSpine Holdings Corporation in the 2nd quarter worth approximately $161,000. Trexquant Investment LP acquired a new stake in SeaSpine Holdings Corporation in the 3rd quarter worth approximately $214,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in SeaSpine Holdings Corporation by 1.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 18,707 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 190 shares in the last quarter. Institutional investors own 39.36% of the company’s stock.

About SeaSpine Holdings Corporation

SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.

Get a free copy of the Zacks research report on SeaSpine Holdings Corporation (SPNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SeaSpine Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.